Among many common malignant tumors, prognostic models based on systemic inflammatory markers (such as the modified Glasgow prognostic score) or comprehensive hematological parameters (such as absolute monocyte count, albumin-to-globulin ratio) have been fully validated.[17–19] These tools greatly assist clinical decision-making. This evidence concerns the gene ALB and cancer.